|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Pfizer |
|---|---|
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00249704 |
Purpose
The study will explore multiple mobility function tests as well as functional and neuropsychological tests in elderly subjects at risk for falls and disability, before and after 4-month exercise and/or Vitamin D intervention.
| Condition | Intervention | Phase |
|---|---|---|
|
Elderly, Frail |
Drug: Vitamin D + Sham Exercise Procedure: Vitamin D Placebo + Exercise Procedure: Vitamin D Placebo + Sham Exercise Drug: Vitamin D + Exercise |
Phase I |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Evaluation of the Effect of a 4-Month Intervention of Exercise and/or Vitamin D on Mobility Function and Strength in Frail Elderly Subjects |
| Enrollment: | 64 |
| Study Start Date: | October 2005 |
| Study Completion Date: | January 2008 |
| Arms | Assigned Interventions |
|---|---|
| Experimental: C |
Procedure: Vitamin D Placebo + Exercise
Vitamin D placebo + Exercise
|
| Experimental: B |
Drug: Vitamin D + Sham Exercise
1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
|
| Experimental: A |
Drug: Vitamin D + Exercise
1000 IU per day of Vitamin D + Exercise
|
| Placebo Comparator: D |
Procedure: Vitamin D Placebo + Sham Exercise
Vitamin D placebo + Sham (equivalent to placebo) Exercise
|
The study was terminated on 10Jan2008. This was a strategic decision not related to safety, efficacy, or feasibility of trial.
Eligibility| Ages Eligible for Study: | 75 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Connecticut | |
| Pfizer Investigational Site | |
| Farmington, Connecticut, United States, 06030-5215 | |
| United States, Maryland | |
| Pfizer Investigational Site | |
| Hyattsville, Maryland, United States, 20782 | |
| United States, Massachusetts | |
| Pfizer Investigational Site | |
| Roslindale, Massachusetts, United States, 02131-1011 | |
| United States, New York | |
| Pfizer Investigational Site | |
| New York, New York, United States, 10040-3403 | |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
| Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
| ClinicalTrials.gov Identifier: | NCT00249704 History of Changes |
| Other Study ID Numbers: | A9001116 |
| Study First Received: | November 3, 2005 |
| Last Updated: | January 7, 2009 |
| Health Authority: | United States: Institutional Review Board |
|
Vitamin D Ergocalciferols Vitamins Bone Density Conservation Agents |
Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |